Vitamin D in hematological disorders and malignancies

Area of Science:

• Biochemistry
• Oncology
• Endocrinology

Background:

• Vitamin D is crucial for calcium homeostasis and bone health.
• Emerging evidence links vitamin D to hematological cancer development and treatment.
• Lower serum 25(OH)D3 levels correlate with poorer outcomes in hematological diseases.

Purpose of the Study:

• To review the current literature on vitamin D's role in hematological cancer.
• To explore vitamin D's potential as an anti-cancer therapy for blood cancers.
• To discuss challenges and advancements in vitamin D-based cancer treatments.

Main Methods:

• Review of existing in vivo and in vitro cancer models.
• Analysis of studies on vitamin D receptor expression in diseased cells.
• Examination of clinical trial data on vitamin D analogs and combinatorial treatments.

Main Results:

• Vitamin D supplementation in abnormal hematological cells promotes apoptosis, induces differentiation, and inhibits proliferation.
• Vitamin D sensitizes tumor cells to other therapies and reduces pro-inflammatory cytokines.
• Vitamin D analogs and combinatorial treatments offer ways to manage potential side effects like hypercalcemia.

Conclusions:

• Vitamin D plays a significant role in hematological cancer pathogenesis and exhibits anti-cancer properties.
• Vitamin D and its analogs are well-tolerated in clinical trials.
• Further clinical research into vitamin D-based therapies for hematological cancers is justified.